.Pharmacolibrary.Drugs.R_RespiratorySystem.R01A_DecongestantsAndOtherNasalPreparationsForTopical.R01AX09_HyaluronicAcid.HyaluronicAcid .Pharmacolibrary.Drugs.R_RespiratorySystem.R01A_DecongestantsAndOtherNasalPreparationsForTopical.R01AX09_HyaluronicAcid.HyaluronicAcid| name: | HyaluronicAcid | |
| ATC code: | R01AX09 | route: | intranasal |
| compartments: | 1 | |
| dosage: | 2 | mg |
| volume of distribution: | 4 | L |
| clearance: | 200 | mL/min |
| other parameters in model implementation | ||
Hyaluronic acid is a naturally occurring glycosaminoglycan widely distributed throughout connective, epithelial, and neural tissues. As a drug, it is commonly used in the treatment of osteoarthritis (via intra-articular injection), as an adjunct in ophthalmic surgery, for wound healing, and as a moisturizer in topical formulations. Intranasal formulations (ATC code R01AX09) have been investigated for improving nasal mucosa hydration. Hyaluronic acid is generally regarded as safe and is used in a variety of medical devices and health products, but is not widely approved as a systemic drug.
Estimated pharmacokinetic parameters for hyaluronic acid administered intranasally in adult subjects. No direct pharmacokinetic studies reporting plasma concentration data or modeling published for this administering route; parameters estimated from general literature on exogenous hyaluronic acid pharmacokinetics.